Acclinate is a health equity company focused on increasing diversity in clinical trials. Its core product is a community engagement platform trusted by top pharmaceutical brands to make existing trials more inclusive and to plan more diverse studies. The company also develops the Enhanced Diversity in Clinical Trials (e-DICT) platform and intends to enhance it with new funding. Acclinate raised $7 million in a Series A to scale its impact and expand its initiatives. The funding will support expansion of its community engagement efforts and initiatives aimed at inclusivity and equity in healthcare. The round brings strategic support from established healthcare organizations to help accelerate Acclinate's work. Acclinate Genetics offers a privacy-protecting digital health platform that uses machine learning and predictive analytics to identify and select more diverse clinical-trial and genomic research participants. The company positions its product to decrease the overall cost of drug development, increase the speed of drug approvals, integrate with virtual clinical trials, and contribute to new drug discovery. Co‑founders Del Smith and Tiffany Jordan‑Whitlow started the company after being personally impacted by the lack of minority representation in medicine. Acclinate recently gained backing from Bronze Valley and became the first bio company in that investor's portfolio. The company says it is focused on educating and engaging diverse individuals to make informed decisions about genomic research and clinical trial participation. Acclinate is seeking additional investors and partners as it continues to grow and scale; the clinical trial patient recruitment market is cited at $3.4 billion today and projected to grow to $5.3 billion by 2030.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

May 2024